2. Search Result
Search Result
Results for "

hepatocyte injury

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

16

Natural
Products

5

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-B0766
    Bicyclol

    SY801

    		 Autophagy Apoptosis HBV HCV HSP Reactive Oxygen Species (ROS) Bcl-2 Family Glutathione S-transferase p38 MAPK NF-κB Microtubule/Tubulin ERK JNK TNF Receptor Interleukin Related CDK Cyclin G-associated Kinase (GAK) mTOR P-glycoprotein Ferroptosis Infection Inflammation/Immunology Cancer
    Bicyclol (SY801) is an orally active derivative of the traditional Chinese medicine Schisandra chinensis, which has antiviral, anti-inflammatory, immunomodulatory, antioxidant, anti-steatosis, anti-fibrotic and anti-tumor activities. Bicyclol regulates the expression of heat shock proteins and plays an anti-apoptosis role in hepatocytes. Bicyclol reduces the activation of NF-κB and the levels of inflammatory factors in hepatocytes infected with hepatitis C virus (HCV) by inhibiting the activation of the ROS-MAPK-NF-κB pathway, and prevents ferroptosis in acute liver injury. Bicyclol can change the expression of Mdr-1, GSH/GST and Bcl-2, increase the intracellular concentration of anticancer drugs, and sensitize drug-resistant cells to anticancer drugs. Bicyclol inhibits the proliferation of human malignant hepatoma cells by regulating the PI3K/AKT pathway and the Ras/Raf/MEK/ERK pathway. Bicyclol can be used in the study of chronic hepatitis, acute liver injury, nonalcoholic fatty liver disease, liver fibrosis and hepatocellular carcinoma .
    Bicyclol
  • HY-113308
    Taurolithocholic acid
    Maximum Cited Publications
    6 Publications Verification

    		 Calcium Channel Ferroptosis PI3K Akt HBV Reactive Oxygen Species (ROS) Cardiovascular Disease Infection Inflammation/Immunology
    Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis (Ferroptosis), viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid
  • HY-103243
    TCPOBOP
    4 Publications Verification

    		 Bcl-2 Family Cancer
    TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss . TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins .
    TCPOBOP
  • HY-N6638
    Retrorsine
    2 Publications Verification

    		 Others Metabolic Disease
    Retrorsine is a naturally occurring toxic pyrrolizidine alkaloid. Retrorsine can bind with DNA and inhibits the proliferative capacity of hepatocytes. Retrorsine can be used for the research of hepatocellular injury .
    Retrorsine
  • HY-113308A
    Taurolithocholic acid sodium salt
    Maximum Cited Publications
    6 Publications Verification

    		 Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Metabolic Disease
    Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid sodium salt
  • HY-Y0651
    Sodium sulfite

    		Environmental Pollutants Biochemical Assay Reagents Infection Inflammation/Immunology
    Sodium sulfite is an inorganic salt used as an antioxidant and preservative. Sodium sulfite is also used in sulfonation and sulfomethylation reactions. Sodium sulfite can also be used as a bleaching agent, desulfurizer, and dechlorinator. Sodium sulfite inhibits hepatocyte proliferation, promotes hepatocyte apoptosis and necrosis, and impairs mitochondrial integrity. Sodium sulfite induces superoxide anion production, primes neutrophils for enhanced superoxide anion generation, and induces neutrophil gene expression. Sodium sulfite can be used in studies related to pulmonary inflammation and gastric tissue injury .
    Sodium sulfite
  • HY-115319
    CP-24879 hydrochloride
    2 Publications Verification

    		 Ferroptosis Inflammation/Immunology
    CP-24879 (hydrochloride) is a potent, selective and combined delta5D/delta6D inhibitor. CP-24879 (hydrochloride) can significantly reduce intracellular lipid accumulation and inflammatory injury in hepatocytes. CP-24879 (hydrochloride) exhibits superior antisteatotic and anti-inflammatory actions in fat-1 and ω-3-treated hepatocytes, and can be used for non-alcoholic steatohepatitis research .
    CP-24879 hydrochloride
  • HY-A0060
    Malotilate

    NKK 105

    		 Lipoxygenase Cancer
    Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
    Malotilate
  • HY-N0912
    Rehmannioside D
    1 Publications Verification

    		 Sirtuin Apoptosis MDM-2/p53 Reactive Oxygen Species (ROS) Bcl-2 Family Caspase Metabolic Disease Inflammation/Immunology
    Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
    Rehmannioside D
  • HY-121983
    CAY10594
    1 Publications Verification

    		 Phospholipase Apoptosis GSK-3 Anaplastic lymphoma kinase (ALK) STAT Interleukin Related G Protein-coupled Receptor Kinase (GRK) CXCR Lactate Dehydrogenase Inflammation/Immunology Cancer
    CAY10594 is an orally active PLD2 inhibitor with an IC50 of 140 nM. CAY10594 has activities such as anti-tumor, anti-oxidation and liver protection. CAY10594 can be used for the research of diseases like breast cancer, acute liver injury and colitis .
    CAY10594
  • HY-157088
    C105SR

    		Caspase Apoptosis Cyclophilin Others
    C105SR is a cyclophilin D (CypD) inhibitor targeting to peptidyl-prolylcis-trans isomerase (PPIase). C105SR inhibits mitochondrial permeability transition opening (mPTP) with an IC 50 of 5 nM. C105SR inhibits hypoxia and reoxygenation inudced hepatocyte apoptosis and increases the level of calcium retention capacity (CRC). C105SR exhibits hepaprotective effect in ischaemia-reperfusion injury (IRI) mouse model .
    C105SR
  • HY-N7133
    Diphenylamine hydrochloride

    N-Phenylaniline hydrochloride

    		 Fungal Bacterial Metabolic Disease
    Diphenylamine hydrochloride (N-Phenylaniline hydrochloride) is an antihyperglycemic agent with oral activity and a common structure in non-steroidal anti-inflammatory drugs (NSAIDs) that uncouples oxidative phosphorylation in mitochondria, leading to a decrease in hepatic cell ATP levels and causing liver cell damage. Diphenylamine hydrochloride is also an industrial antioxidant, a dyeing mordant, and is used in agriculture as an antifungal and antibacterial agent .
    Diphenylamine hydrochloride
  • HY-N4124
    Poricoic acid B

    		NO Synthase TNF Receptor Interleukin Related Metabolic Disease Inflammation/Immunology
    Poricoic acid B is a triterpenoid compound that can be isolated from Poria cocos. Poricoic acid B inhibits intracellular lipid accumulation and reduces the levels of hepatocyte injury markers. Poricoic acid B inhibits the production of NO, TNF-α, IL-1β and IL-6, thereby exerting anti-inflammatory activity. Poricoic acid B can be used in the research of metabolic dysfunction-associated fatty liver disease and inflammatory diseases [3].
    Poricoic acid B
  • HY-170495
    HDAC6 degrader-5

    		HDAC Apoptosis Interleukin Related Inflammation/Immunology
    HDAC6 degrader-5 (Compound 6) exhibits inhibitory and degradation activity against HDAC6, with an IC50 of 4.95 nM and a DC50 of 0.96 nM. HDAC6 degrader-5 inhibits the release of TNF-α, IL-1β and IL-6, blocks the hepatocyte apoptosis. HDAC6 degrader-5 exhibits anti-inflammatory activity in mouse APAP (HY-66005)-induced liver injury models .
    HDAC6 degrader-5
  • HY-N12378
    β-Patchoulene

    		NF-κB Toll-like Receptor (TLR) PKA Epigenetic Reader Domain Keap1-Nrf2 Sirtuin AMPK Caspase FASTK ERK ROCK Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    β-Patchoulene is an orally active anti-inflammatory, antioxidant, and anti-apoptotic agent. β-Patchoulene inhibits the NF-κB, TLR4, and cAMP/PKA/CREB signaling pathways; activates the Sirt1/Nrf2 and AMPK signaling pathways; and targets Fas/FasL, Caspase-3, ERK1/2, ROCK1/MLC2 for inhibition. β-Patchoulene regulates cytokine secretion, inflammatory cell infiltration, lipid peroxidation, cell polarization, gut microbiota, and lipid metabolism, restores barrier function, mitochondrial function, and cell viability, and exhibits repellent activity against Spodoptera exigua larvae. β-Patchoulene can be used in research related to various inflammatory, ischemic, fibrosis-associated diseases, as well as hepatocellular carcinoma .
    β-Patchoulene
  • HY-113308S1
    Taurolithocholic acid-d4

    		Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Others
    Taurolithocholic acid-d4 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid-d4
  • HY-176274
    FASN/SCD-IN-1

    		Fatty Acid Synthase (FASN) Stearoyl-CoA Desaturase (SCD) Reactive Oxygen Species (ROS) Interleukin Related TNF Receptor SOD LDLR Glutathione Peroxidase Metabolic Disease Inflammation/Immunology
    FASN/SCD-IN-1 is a Silybin (HY-N0779A) derivative, an orally active inhibitor of Fatty Acid Synthase (FASN)/Stearoyl-CoA Desaturase (SCD). FASN/SCD-IN-1 has shown in vitro activity in inhibiting lipid deposition, reducing FASN and SCD transcriptional levels, and exhibiting antioxidant, anti-inflammatory, and anti-fibrotic activities. FASN/SCD-IN-1 has demonstrated significant hepatoprotective effects in a rat model of acute liver injury. FASN/SCD-IN-1 ameliorates the pathological features of MASH liver, including steatosis, inflammation, and fibrosis in a mouse model of myeloproliferative steatohepatitis (MASH). FASN/SCD-IN-1 can be used to study MASH .
    FASN/SCD-IN-1
  • HY-113308AR
    Taurolithocholic acid sodium salt (Standard)

    		Reference Standards Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Metabolic Disease
    Taurolithocholic acid (sodium salt) (Standard) is the analytical standard of Taurolithocholic acid (sodium salt). This product is intended for research and analytical applications. Taurolithocholic acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid sodium salt (Standard)
  • HY-113308AS1
    Taurolithocholic Acid-d5 sodium salt

    		Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Metabolic Disease
    Taurolithocholic Acid-d5 (sodium) is the deuterium labeled Taurolithocholic acid sodium salt. Taurolithocholic Acid sodium salt is an orally active bile acid and antiviral agent. Taurolithocholic Acid sodium salt upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic Acid sodium salt also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic Acid sodium salt serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic Acid sodium salt shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic Acid sodium salt not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic Acid-d5 sodium salt
  • HY-103243R
    TCPOBOP (Standard)

    		Reference Standards Bcl-2 Family Cancer
    TCPOBOP (Standard) is the analytical standard of TCPOBOP. This product is intended for research and analytical applications. TCPOBOP is a constitutive androstane receptor (CAR) agonist that induces robust hepatocyte proliferation and hepatomegaly without any liver injury or tissue loss . TCPOBOP attenuates Fas-induced murine liver injury by altering Bcl-2 proteins .
    TCPOBOP (Standard)
  • HY-N15691
    Tadehaginoside

    		Keap1-Nrf2 NF-κB Metabolic Disease Inflammation/Immunology
    Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .
    Tadehaginoside
  • HY-N15691A
    (E)-Tadehaginoside

    		Keap1-Nrf2 NF-κB Metabolic Disease Inflammation/Immunology
    (E)-Tadehaginoside is the E-isomer of Tadehaginoside (HY-N15691). Tadehaginoside, a phenylpropanoid glycoside, is a regulator of lipogenesis and glucose consumption. Tadehaginoside has antioxygenic property. Tadehaginoside mediates liver protection against oxidative stress injury and inflammation by regulating Nrf2 and NF-κB signaling pathways in hepatocytes. Tadehaginoside can be used for the study of obesity and diabetes .
    (E)-Tadehaginoside
  • HY-A0060R
    Malotilate (Standard)

    NKK 105 (Standard)

    		 Lipoxygenase Reference Standards Cancer
    Malotilate (Standard) is the analytical standard of Malotilate. This product is intended for research and analytical applications. Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes .
    Malotilate (Standard)
  • HY-N0912R
    Rehmannioside D (Standard)

    		Reference Standards Reactive Oxygen Species (ROS) Metabolic Disease Inflammation/Immunology
    Rehmannioside D (Standard) is the analytical standard of Rehmannioside D (HY-N0912). This product is intended for research and analytical applications. Rehmannioside D is an orally active Sirt7 modulator. Rehmannioside D upregulates Sirt7 expression, inhibits the level of acetylated p53, and blocks the activation of the p53 signaling pathway. Rehmannioside D alleviates liver injury, inflammatory response, collagen deposition and hepatocyte apoptosis. Rehmannioside D is applicable to research related to liver fibrosis .
    Rehmannioside D (Standard)
  • HY-162584
    TRPC5-IN-6

    		TRP Channel Others
    TRPC5-IN-6 (Compound 12) is an orally effective transient receptor potential (TRPC5) inhibitor with a IC50 value of 81 nM. TRPC5-IN-6 has good biosafety and low liver and kidney toxicity, and is expected to play an important role in the treatment of chronic kidney disease (CKD) .
    TRPC5-IN-6
  • HY-113308AS
    Taurolithocholic acid-d4 sodium

    		Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Metabolic Disease
    Taurolithocholic acid-d4 (sodium) is the deuterium labeled Taurolithocholic acid (sodium salt). Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid-d4 sodium
  • HY-113308AS2
    Taurolithocholic acid-d4-1 sodium

    		Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Metabolic Disease
    Taurolithocholic acid-d4-1 (sodium) is the deuterium labeled Taurolithocholic acid. Taurolithocholic acid sodium is an orally active bile acid and antiviral agent. Taurolithocholic acid sodium upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid sodium also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid sodium serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid sodium shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid sodium not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid-d4-1 sodium
  • HY-113308S
    Taurolithocholic acid-d5

    		Isotope-Labeled Compounds Calcium Channel Ferroptosis PI3K Reactive Oxygen Species (ROS) Akt HBV Others
    Taurolithocholic acid-d5 is deuterium labeled Taurolithocholic acid. Taurolithocholic acid is an orally active bile acid and antiviral agent. Taurolithocholic acid upregulates FADS2 by activating the TGR5-PI3K/AKT-SREBP2 signaling axis, inhibits SFTSV-induced ferroptosis, viral replication and viral entry of HBV/HDV, while reducing the release of IL-1β, lipid ROS and LDH. While exerting antiviral protective effects, Taurolithocholic acid also stimulates the recycling of hepatocellular membrane transporters, impairs canalicular bile acid secretion function, and induces hepatocyte cholestasis, apoptosis and acute hepatocellular injury. Taurolithocholic acid serves as an experimental model compound for hepatocellular cholestasis. At concentrations ≤200 μM, Taurolithocholic acid shows no cytotoxicity and does not activate the interferon pathway. Taurolithocholic acid not only protects mice from lethal SFTSV infection but also is suitable for studies related to severe fever with thrombocytopenia syndrome and cholestasis .
    Taurolithocholic acid-d5
  • HY-N17882A
    Hydroxysaikosaponin D

    		Drug Derivative Metabolic Disease
    Hydroxysaikosaponin D is a hepatocytoprotective saponin found in the roots of Bupleurum scorzonerifolium WILLD. Hydroxysaikosaponin D inhibits D-galactosamine-induced cytotoxicity in primary cultured rat hepatocytes. Hydroxysaikosaponin D mitigates D-galactosamine/LPS-induced liver injury in mice. Hydroxysaikosaponin D can be used for the research of liver injury .
    Hydroxysaikosaponin D
  • HY-111096
    IDN-7314

    		Caspase Cardiovascular Disease Metabolic Disease
    IDN-7314 is a pan-Caspase inhibitor with an IC50 of 0.2-7 nM against all tested Caspases. IDN-7314 abrogates Jo2-induced caspase-3/7 activity. IDN-7314 reduces the procoagulant activity of tissue factor in hepatocytes. IDN-7314 is applicable to research related to chemically induced hepatitis, fulminant liver failure and apoptotic liver injury .
    IDN-7314
  • HY-N15464
    Antihepatotoxic agent-1

    		Aldehyde Dehydrogenase (ALDH) Metabolic Disease
    Antihepatotoxic agent-1 is a cerebroside present in Lycium chinense Fruits with antihepatotoxic activity. Antihepatotoxic agent-1 exerts a protective effect by blocking the release of alanine aminotransferase and sorbitol dehydrogenase from primary cultured rat hepatocytes intoxicated with carbon tetrachloride. Antihepatotoxic agent-1 can be used in studies related to liver injury .
    Antihepatotoxic agent-1
  • HY-P992072
    Anti-Human/Mouse CD95 Antibody (HFE7A)

    		Apoptosis Caspase Metabolic Disease
    Anti-Human/Mouse CD95 Antibody (HFE7A) is an antibody targeting human/mouse Fas (CD95), with a Kd of 1.6 nM in mice. Anti-Human/Mouse CD95 Antibody (HFE7A) modulates the Fas-mediated apoptotic signaling pathway without blocking the binding of Jo2 to Fas. Anti-Human/Mouse CD95 Antibody (HFE7A) inhibits Jo2-induced caspase activation, mitochondrial depolarization, hepatocyte death and apoptosis. Anti-Human/Mouse CD95 Antibody (HFE7A) protects BALB/c mice against Jo2-induced acute liver injury and reduces Jo2-associated elevation of serum transaminase levels. Anti-Human/Mouse CD95 Antibody (HFE7A) can be used in studies related to liver injury. For isotype control, refer to Mouse IgG1 kappa, Isotype Control (HY-P99977) .
    Anti-Human/Mouse CD95 Antibody (HFE7A)
  • HY-N13285
    (-)-Epigallocatechin-4'-O-methylether

    (-)-EGC-4'-O-ME

    		 Drug Derivative Metabolic Disease Inflammation/Immunology
    (-)-Epigallocatechin-4'-O-methylether ((-)-EGC-4'-O-ME) is an orally active natural phenolic catechin with antioxidant, free radical-scavenging and hepatoprotective activities. (-)-Epigallocatechin-4'-O-methylether interferes with radiation-induced free radical formation, scavenges DPPH free radicals, inhibits carbon tetrachloride-induced increases in serum GOT and GPT, suppresses carbon tetrachloride-induced TBA-RS formation, and counteracts carbon tetrachloride-induced hepatocyte toxicity. (-)-Epigallocatechin-4'-O-methylether binds specifically to human serum albumin. (-)-Epigallocatechin-4'-O-methylether can be used in studies related to liver injury .
    (-)-Epigallocatechin-4'-O-methylether
  • HY-W714300
    Nuarimol

    		Fungal Infection
    Nuarimol is a fungicide used for plant protection in agriculture. Nuarimol is a phenobarbital-type inducer of hepatic drug-metabolizing enzymes. It triggers transient but robust regenerative hepatocyte proliferation accompanied by hepatomegaly by causing reversible hepatocellular injury .
    Nuarimol
  • HY-182294
    HYJ-2

    		URAT1 Metabolic Disease Inflammation/Immunology
    HYJ-2 is a URAT1 inhibitor and urate-lowering agent. HYJ-2 inhibits URAT1-mediated urate transport and interacts with key residues within the URAT1 binding pocket. HYJ-2 reduces serum urate levels in hyperuricemic mice without inducing liver or kidney injury. HYJ-2 shows low cytotoxicity to hepatocytes and renal cells. HYJ-2 does not significantly induce hepatocyte apoptosis or mitochondrial dysfunction. HYJ-2 can be used in studies related to hyperuricemia and gout .
    HYJ-2
  • HY-N18297
    Licoagrochalcone A

    		Phosphatase Metabolic Disease
    Licoagrochalcone A is a PTP1B inhibitor. Licoagrochalcone A exerts protective effects against liver cell injury induced by carbon tetrachloride and Acetaminophen (HY-66005). Licoagrochalcone A is applicable to the research of type 2 diabetes, obesity and liver injury .
    Licoagrochalcone A
  • HY-N17410
    Umbellatolide A

    		Drug Derivative Others
    Umbellatolide A is an 11-noriridoid found in the aerial parts of Morinda umbellata. Umbellatolide A shows no significant cytotoxic activity against human cancer cells .
    Umbellatolide A
  • HY-183995
    SH-26

    		PROTACs HIF/HIF Prolyl-Hydroxylase Reactive Oxygen Species (ROS) NOD-like Receptor (NLR) Metabolic Disease
    SH-26 is a PHD1 PROTAC degrader with DC50s of 1.06 μM, 4.16 μM and 4.91 μM in MDA-MB-231, HepG2 and HEK-293T cells, respectively. SH-26 recruits CRBN to induce PHD1 degradation via the ubiquitin-proteasome system. SH-26 attenuates APAP (HY-66005)-triggered ROS accumulation, mitochondrial dysfunction, and NLRP3 inflammasome activation. SH-26 can be used for the research of acute liver injury .
    SH-26
  • HY-149043
    NIK-IN-1

    		NF-κB Metabolic Disease
    NIK-IN-1 (Compound 2) is an inhibitor of NF-κB-inducing kinase (NIK). NIK-IN-1 is used for research on hepatic inflammatory diseases and acute liver injury .
    NIK-IN-1
  • HY-N17495
    Luteolin 7-O-(6-O-malonyl-β-D-glucoside)

    		Others Metabolic Disease
    Luteolin 7-O-(6-O-malonyl-β-D-glucoside) is an orally active flavonoid free radical scavenger. Luteolin 7-O-(6-O-malonyl-β-D-glucoside) scavenges free radicals, inhibits the activity elevation of aspartate aminotransferase and alanine aminotransferase in mouse plasma, as well as the elevation of liver lipid hydroperoxide content. Luteolin 7-O-(6-O-malonyl-β-D-glucoside) is applicable for liver injury research .
    Luteolin 7-O-(6-O-malonyl-β-D-glucoside)

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: